Key Points
- CEO Bradley Campbell sold 14,587 shares on Dec. 1 at an average price of $10.01 for about $146,016, reducing his stake by 1.27% to 1,137,282 shares (SEC filing).
- Amicus beat the quarter with EPS of $0.17 vs. $0.12 expected and revenue of $169.06M (up 19.5% YoY), but the company still reports a negative net margin and a trailing negative PE of -244.
- Analyst/institutional interest is constructive: consensus rating is "Moderate Buy" with an average target of $16.57, while firms like Goldman Sachs and Needham have recently raised targets and large holders (Vanguard, Wellington) own tens of millions of shares.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 14,587 shares of the firm's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $10.01, for a total value of $146,015.87. Following the sale, the chief executive officer directly owned 1,137,282 shares in the company, valued at approximately $11,384,192.82. This trade represents a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Amicus Therapeutics Trading Up 0.5%
Shares of NASDAQ:FOLD opened at $9.78 on Thursday. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $10.57. The business has a 50 day moving average of $8.88 and a two-hundred day moving average of $7.47. The company has a market capitalization of $3.02 billion, a PE ratio of -244.44 and a beta of 0.46.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same period in the previous year, the firm earned $0.10 EPS. The business's quarterly revenue was up 19.5% on a year-over-year basis. As a group, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.
Institutional Investors Weigh In On Amicus Therapeutics
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 29,534,029 shares of the biopharmaceutical company's stock valued at $232,728,000 after acquiring an additional 126,441 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 2.6% during the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company's stock worth $238,277,000 after purchasing an additional 738,623 shares in the last quarter. William Blair Investment Management LLC raised its stake in Amicus Therapeutics by 7.6% in the 3rd quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company's stock valued at $124,104,000 after purchasing an additional 1,107,083 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company's stock valued at $68,187,000 after purchasing an additional 7,625,000 shares in the last quarter. Finally, State Street Corp lifted its holdings in Amicus Therapeutics by 21.5% in the 2nd quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company's stock valued at $66,285,000 after purchasing an additional 2,049,078 shares in the last quarter.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. The Goldman Sachs Group upped their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 5th. Zacks Research raised Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Wall Street Zen raised Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Monday. Finally, Needham & Company LLC upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price on the stock in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $16.57.
View Our Latest Analysis on Amicus Therapeutics
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
